T1	Action 487 497	inhibition
T2	Concept 476 486	SARS-CoV-2
R1	subject Arg1:T1 Arg2:T2	
T3	Concept 507 516	sensitive
A1	Emphasized T3
R2	target Arg1:T1 Arg2:T3	
T4	Concept 520 539	crRNA concentration
R3	in-context Arg1:T3 Arg2:T4	
T5	Concept 543 554	our samples
R4	in-place Arg1:T3 Arg2:T5	
T6	Concept 568 585	Cas13d expression
A2	Diminished T6
T7	Action 602 611	decreased
T8	Concept 591 601	moderately
R5	has-property Arg1:T7 Arg2:T8	
R6	subject Arg1:T7 Arg2:T6	
T9	Concept 612 631	inhibitory activity
R7	target Arg1:T7 Arg2:T9	
T10	Concept 10 30	SARS-CoV-2 infection
T11	Concept 39 49	viral load
A3	Emphasized T11
T13	Concept 54 67	overexuberant
T12	Concept 73 88	immune response
T14	Concept 68 72	host
R8	in-context Arg1:T12 Arg2:T14	
R9	has-property Arg1:T12 Arg2:T13	
T15	Concept 99 105	innate
T16	Concept 110 118	acquired
R10	in-context Arg1:T12 Arg2:T15	
R11	in-context Arg1:T12 Arg2:T16	
T17	Action 144 155	contributes
R12	subject Arg1:T17 Arg2:T11	
R13	subject Arg1:T17 Arg2:T12	
T18	Concept 163 175	pathogenesis
T19	Concept 179 187	COVID-19
R14	in-context Arg1:T18 Arg2:T19	
T20	Concept 192 204	organ injury
R15	target Arg1:T17 Arg2:T18	
R16	target Arg1:T17 Arg2:T20	
R17	in-context Arg1:T11 Arg2:T10	
R18	in-context Arg1:T12 Arg2:T10	
